Cisplatin News and Research

RSS

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and an application for marketing authorization to the European Medicines Agency for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

1 Jul 2013

Study describes molecular bases of resistance to new chemotherapeutic agent in familial breast and ovarian cancers

It is estimated that between 5% and 10% of breast and ovarian cancers are familial in origin, which is to say that these tumours are attributable to inherited mutations from the parents in genes such as BRCA1 or BRCA2.

19 Jun 2013

Scientists discover molecular pathway that can prevent death of oocytes due to chemotherapy

Young women who have cancer treatment often lose their fertility because chemotherapy and radiation can damage or kill their immature ovarian eggs, called oocytes. Now, Northwestern Medicine- scientists have found the molecular pathway that can prevent the death of immature ovarian eggs due to chemotherapy, potentially preserving fertility and endocrine function.

18 Jun 2013

Studies demonstrate that combined therapy could destroy drug-resistant cells within melanoma tumor

Advanced metastatic melanoma is a disease that has proven difficult to eradicate. Despite the success of melanoma-targeting drugs, tumors inevitably become drug resistant and return, more aggressive than before. In the current issue of the journal Cancer Cell, however, researchers at The Wistar Institute describe how they increase the effectiveness of anti-melanoma drugs by combining anticancer therapies with diabetes drugs.

12 Jun 2013

Stephen J. Lippard to receive 2014 Priestley Medal from American Chemical Society

Stephen J. Lippard, Ph.D., Arthur Amos Noyes Professor of Chemistry at the Massachusetts Institute of Technology and associate editor of the Journal of the American Chemical Society, will receive the 2014 Priestley Medal from the American Chemical Society.

11 Jun 2013

Researchers demonstrate how modified citrus pectin works against cancer

A new review by researchers at the University of Maryland School of Medicine highlights a large body of published research demonstrating how modified citrus pectin, works against cancer.

4 Jun 2013

Early detection methods can help cure cervical cancer

Cervical cancer, a disease that will affect more than 12,000 women in the United States this year and more than a half million women worldwide, leads to significantly fewer deaths when effective early detection methods are available, either via a Pap smear or with a test for presence of the human papilloma virus.

4 Jun 2013

Study supports future possibility of personalized medicine for cervical cancer

Doctors at Washington University School of Medicine in St. Louis have shown that testing cervical tumors before treatment for vulnerability to chemotherapy predicts whether patients will do well or poorly with standard treatment.

1 Jun 2013

Ruthenium complexes could pave way for cancer treatments, say UT Arlington researchers

A team of UT Arlington researchers has identified two ruthenium-based complexes they believe could pave the way for treatments that control cancer cell growth more effectively and are less toxic for patients than current chemotherapies.

30 May 2013

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar (sorafenib) tablets, Stivarga (regorafenib) tablets and the recently U.S. Food and Drug Administration approved product Xofigo (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology, May 31 – June 4, in Chicago, IL (USA).

16 May 2013

Study underscores new paradigm in cancer therapy

In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers.

16 May 2013

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma who have progressed on Nexavar (sorafenib) tablets, an anticancer medicine for the treatment of patients with unresectable HCC.

15 May 2013

Study: Combination of chemotherapy and nerve-protecting agents can prevent anemia

Cancer chemotherapy can cause peripheral neuropathy-nerve damage often resulting in pain and muscle weakness in the arms and legs. Now, researchers at Albert Einstein College of Medicine of Yeshiva University have discovered that chemo also induces an insidious type of nerve damage inside bone marrow that can cause delays in recovery after bone marrow transplantation.

6 May 2013

Clinical study shows association between results of ChemoFx and RFS of cervical cancer patients

A clinical study reporting an association between the results of the ChemoFx chemoresponse assay and recurrence free survival of cervical cancer patients has been accepted for publication by Gynecologic Oncology.

30 Apr 2013

Two abstracts related to Advaxis' ADXS-HPV selected for poster presentation at ASCO meeting

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that two abstracts related to ADXS-HPV (ADXS11-001), the Company's lead clinical stage product candidate, have been selected for poster presentation at the 2013 American Society of Clinical Oncology Annual Meeting in Chicago, IL, from May 31 - June 4, 2013, at the McCormick Place Convention Center.

18 Apr 2013

Preclinical studies show bladder cancers, mesotheliomas respond to treatment with ADI-PEG 20

Scientists from academic institutions reported at the 2013 annual American Association for Cancer Research meeting, results from preclinical studies which showed that certain bladder cancers and mesotheliomas have metabolic changes and are more likely to respond to treatment with ADI-PEG 20 (pegylated arginine deiminase) if they are deficient in the enzyme, argininosuccinate synthetase.

18 Apr 2013

New data on use of PBD dimers as warheads in ADCs presented at AACR annual meeting

Spirogen, a leading oncology-focused company developing DNA sequence targeted agents, and BioAtla LLC, a San Diego headquartered antibody therapeutics developer, today announced new data on the use of pyrrolobenzodiazepine (PBD) dimers as warheads in antibody drug conjugates (ADCs) at the annual meeting of the American Association for Cancer Research (AACR) in Washington, DC.

11 Apr 2013

PARP inhibitors can be novel treatment strategy for cisplatin-resistant cancer

Poly (ADP-ribose) polymerase inhibitors may be a novel treatment strategy for patients with cancer that has become resistant to the commonly used chemotherapy drug cisplatin, according to data from a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research.

3 Apr 2013

Study on neoadjuvant cisplatin-based chemotherapy presented at 28th Annual EAU Congress

At the 28th Annual EAU Congress currently ongoing in Milan until Tuesday, W. Tan and colleagues presented their study on neoadjuvant cisplatin-based chemotherapy which showed that epigenetic changes are potential key drivers in the development of chemo resistance in bladder cancer.

18 Mar 2013

EpiCept fourth quarter revenue decreases to $0.1 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2012, and provided an update on the Company's merger with Immune Pharmaceuticals, Ltd. (Immune).

28 Feb 2013